Lexaria Bioscience Corp (LEXX)
3.28
+0.21 (+6.84%)
USD |
NASDAQ |
Jun 24, 16:00
3.28
0.00 (0.00%)
After-Hours: 18:19
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 19.52M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -53.77% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 64.92 |
| Price to Book Value | 1.704 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0007 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 97.33% |
News
Headline
Wire
Time (ET)
SA Breaking News
06/21 10:24
SA Breaking News
06/21 10:03
SA Breaking News
06/08 10:13
MT Newswires
06/03 04:17
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 07/15/2022* | -- | Results | Q3 2022 | -- | -0.28 | -- | |
| 01/14/2022 | -- | Results | Q1 2022 | -- | -- | -- | |
| 11/29/2021 | -- | Results | Q4 2021 | -- | -- | -- | |
| 07/15/2021 | -- | Results | Q3 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio. |
| URL | https://www.lexariabioscience.com |
| Investor Relations URL | http://www.lexariaenergy.com/investors/ |
| HQ State/Province | British Columbia |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Jul. 15, 2022 (est.) |
| Last Earnings Release | Jan. 14, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of June 23, 2022.
Fundamentals
| Revenue (TTM) | 0.2796M |
| Total Expenses (TTM) | 7.657M |
| Net Income (TTM) | -7.154M |
| Total Assets (Quarterly) | 11.41M |
| Total Liabilities (Quarterly) | 0.1946M |
| Shareholders Equity (Quarterly) | 11.46M |
| Cash from Operations (TTM) | -4.712M |
| Cash from Investing (TTM) | -0.1634M |
| Cash from Financing (TTM) | 3.971M |
Ratings
Profile
Edit
| Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio. |
| URL | https://www.lexariabioscience.com |
| Investor Relations URL | http://www.lexariaenergy.com/investors/ |
| HQ State/Province | British Columbia |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Jul. 15, 2022 (est.) |
| Last Earnings Release | Jan. 14, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| LEXX Tweets |